← Russell 3000 cross-section

PRCT PROCEPT BioRobotics Corp

Trailing twelve months to 2026-06-30 · as filed 2026-08-05, not restated
Healthcare

Scale

Market cap
$1.2bn
Revenue TTM
$337m
Net income TTM
$-110m
Free cash flow
$-85m
Composite score
44.9
Sector rank
#1928

Valuation

P / E
EV / EBITDA
EV / sales
3.0
FCF yield
-7.15%
Earnings yield vs 10-yr
-13.97pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-32.5%
EBITDA margin
-31.8%
ROE
-32.3%
ROIC
-69.7%
Revenue growth
22.7%

Insider activity, last 90 days

Net open-market
$0.47m
Buyers
1
Sellers
3

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Under the Agreement, if the Company maintains less than $ 100.0 million in available cash, then the Company is required to meet either one of two financial covenants: a minimum unrestricted cash covenant or a minimum revenue and growth covenant. Revenue The following table presents revenue disaggregated by type and geography (in thousands): During the three and six months ended June 30, 2026, the Company recognized $ 5.7 million and $ 9.2 million of revenue, respectively, that was included in the deferred revenue balance as of March 31, 2026 and December 31, 2025. …PROCEPT BioRobotics Corp, 10-Q, period ended 2026-06-30, filed 2026-08-05

Read the full passage →